DJIA52538.49 160.92
S&P 5007739.82 17.22
NASDAQ26465.69 -12.12
Russell 20002818.64 -0.23
German DAX25688.88 82.23
FTSE 10010696.10 9.56
CAC 407886.73 -0.41
EuroStoxx 506166.05 1.40
Nikkei 22563954.19 685.82
Hang Seng23094.83 53.51
Shanghai Comp3681.47 33.17
KOSPI6012.44 374.10
Bloomberg Comm IDX142.85 0.94
WTI Crude-fut115.56 1.61
Brent Crude-fut103.46 3.61
Natural Gas3.49 0.00
Gasoline-fut3.09 0.03
Gold-fut4058.00 -19.00
Silver-fut53.71 -0.83
Platinum-fut1548.50 1.90
Palladium-fut1015.00 -21.00
Copper-fut6.65 -0.01
Aluminum-spot3195.00 0.00
Coffee-fut285.40 -8.85
Soybeans-fut1244.25 1.00
Wheat-fut598.75 -12.25
Bitcoin80488.65 -414.98
Ethereum USD2331.46 -19.83
Litecoin58.49 1.62
Dogecoin0.08 0.00
EUR/USD1.1144 -0.0042
USD/JPY157.85 0.19
GBP/USD1.3324 -0.0036
USD/CHF0.8285 0.0009
USD IDX102.35 0.01
US 10-Yr TR5.032 0.039
GER 10-Yr TR3.3835 0.0281
UK 10-Yr TR5.3457 0.0098
JAP 10-Yr TR2.831 0.006
Fed Funds4 0
SOFR3.95 0.02
High-rise commercial buildings

Sub Markets

Topics

Alternative Assets  + Private Equity  | 
Patient Square Forms $300M Company for Medical Device Startups

Patient Square Forms $300M Company for Medical Device Startups

Patient Square Capital, a Menlo Park, CA-based healthcare investment firm, has created and committed $300 million to Elevage Medical Technologies; a new portfolio company intended to support growth in the medical device industry.

Elevage Medical Technologies, which is currently a remote company without a corporate headquarters, will follow a similar strategy of Patient Square’s Enavate Sciences, which made its debut nearly a year ago. Both aim to provide financial support and lend their experience to startups looking to build out their technical and clinical operations.

“This is an exciting time for innovation in the medical device field, and through Elevage Medical Technologies, we will support the growth of new, life-changing technologies to impact patient care,” said newly appointed CEO Evan Melrose.

Melrose most recently served as the founding managing director of healthcare investment firm Spindletop Capital. Before that, he held executive titles at two other venture capital firms – PTV Sciences and Burrill & Company.

Patient Square’s launch comes a few weeks after it closed its debut fund with approximately $3.9 billion, bringing its total assets to roughly $5.9 billion. Its portfolio includes Apollo Therapeutics, hearing aid developer Eargo and gene therapy weaver Kriya Therapeutics.

Connect

Inside The Story

Elevage Medical TechnologiesPatient Square Capital

About Joe Palmisano

Joe Palmisano is editorial director of Connect Money, where he oversees daily coverage of alternative assets, direct investments, financial advisory and the economy. He brings three decades of experience as a financial journalist, analyst and portfolio manager. Before joining Connect Money, Palmisano wrote for The Wall Street Journal, covering foreign exchange, global fixed-income and equity markets. He later served as a senior research analyst and portfolio manager, producing market analysis and managing foreign exchange and U.S. equity portfolios for FX Concepts. His work has also appeared in SFO Magazine and CMT Association publications. Palmisano earned a bachelor’s degree in finance from The American University and holds the Chartered Market Technician (CMT) designation and is a member of the CFA Institute.